• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

Research Briefing on Gemcitabine Diphosphate Choline (1643126-46-8): Recent Advances and Therapeutic Potential

Gemcitabine Diphosphate Choline (GDC), with the chemical identifier 1643126-46-8, represents a novel prodrug derivative of gemcitabine, a well-established nucleoside analog widely used in chemotherapy for various cancers, including pancreatic, breast, and non-small cell lung cancers. Recent studies have focused on enhancing the therapeutic efficacy and reducing the systemic toxicity of gemcitabine through structural modifications, with GDC emerging as a promising candidate due to its improved pharmacokinetic properties and targeted delivery mechanisms.

The primary objective of recent research on GDC has been to evaluate its bioactivation pathways, cellular uptake, and antitumor activity in comparison to conventional gemcitabine. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that GDC exhibits superior membrane permeability, attributed to the choline moiety, which facilitates enhanced intracellular accumulation of the active metabolite, gemcitabine diphosphate. This property is particularly advantageous in overcoming drug resistance mechanisms associated with reduced nucleoside transporter expression in tumor cells.

In vitro and in vivo studies have revealed that GDC maintains potent cytotoxic activity against gemcitabine-resistant cancer cell lines, with IC50 values significantly lower than those observed for gemcitabine alone. Mechanistic investigations indicate that GDC undergoes rapid enzymatic conversion to gemcitabine monophosphate within tumor cells, followed by phosphorylation to the active diphosphate and triphosphate forms. This metabolic activation profile suggests a reduced reliance on deoxycytidine kinase, a critical enzyme often downregulated in gemcitabine-resistant tumors.

Pharmacokinetic analyses in animal models have shown that GDC achieves higher tumor-to-plasma ratios compared to gemcitabine, with prolonged retention in tumor tissues. This targeted biodistribution is believed to result from both passive accumulation via the enhanced permeability and retention (EPR) effect and active uptake through choline transporters overexpressed in many malignancies. These findings were corroborated by PET imaging studies using radiolabeled GDC analogs, which visualized preferential tumor uptake in xenograft models.

Clinical translation of GDC faces several challenges that current research aims to address. Stability studies have identified optimal formulation conditions to prevent premature hydrolysis of the diphosphate-choline linkage in circulation. Additionally, combination therapy approaches are being explored, with preliminary data suggesting synergistic effects when GDC is administered with checkpoint inhibitors or other targeted therapies. The compound's potential to bypass key resistance mechanisms while maintaining a favorable safety profile positions it as a strong candidate for further development in precision oncology applications.

Future research directions include comprehensive toxicology assessments, scale-up synthesis optimization, and the development of companion diagnostics to identify patient populations most likely to benefit from GDC therapy. The unique chemical properties of 1643126-46-8 continue to inspire derivative design, with several analogs currently in preclinical evaluation for improved tissue specificity and reduced off-target effects.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)